Therapies for type 1 diabetes: current scenario and future perspectives
V Pathak, NM Pathak, CL O'Neill… - Clinical Medicine …, 2019 - journals.sagepub.com
Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells
located in the endocrine pancreas in areas known as islets of Langerhans. The current …
located in the endocrine pancreas in areas known as islets of Langerhans. The current …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use
H Haahr, EG Fita, T Heise - Clinical pharmacokinetics, 2017 - Springer
Insulin degludec/insulin aspart (IDegAsp; 70% IDeg and 30% IAsp) is a soluble combination
of two individual insulin analogues in one product, designed to provide mealtime glycaemic …
of two individual insulin analogues in one product, designed to provide mealtime glycaemic …
Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials
E Mannucci, C Caiulo, L Naletto, G Madama… - Endocrine, 2021 - Springer
Aim The aim of the present network meta-analysis is to assess the efficacy and safety across
different long and short-acting analogs for the treatment of type 2 diabetes. Methods A …
different long and short-acting analogs for the treatment of type 2 diabetes. Methods A …
Use of insulin degludec/insulin aspart in the management of diabetes mellitus: expert panel recommendations on appropriate practice patterns
T Demir, S Turan, K Unluhizarci, O Topaloglu… - Frontiers in …, 2021 - frontiersin.org
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec
(IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which …
(IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which …
Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: a real-world, prospective, non-interventional study across six countries
GR Fulcher, S Akhtar, SJ Al-Jaser, J Medina… - Advances in …, 2022 - Springer
Introduction Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of
insulin degludec (a basal insulin) and insulin aspart (a prandial insulin). The aim of this …
insulin degludec (a basal insulin) and insulin aspart (a prandial insulin). The aim of this …
Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances
Diabetes is a chronic condition which affects the glucose metabolism in the body. In lieu of
any clinical “cure,” the condition is managed through the administration of pharmacological …
any clinical “cure,” the condition is managed through the administration of pharmacological …
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison
PD Home, R Mehta, KAS Hafidh… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of basal insulin
glargine 100 U/mL and lixisenatide (glucagon‐like peptide‐1 receptor agonist) versus …
glargine 100 U/mL and lixisenatide (glucagon‐like peptide‐1 receptor agonist) versus …
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
R Mehta, R Chen, T Hirose, M John… - Diabetes, Obesity …, 2020 - Wiley Online Library
Insulin degludec/insulin aspart (IDegAsp) is a fixed‐ratio co‐formulation of insulin degludec,
which provides long‐lasting basal insulin coverage, and insulin aspart, which targets …
which provides long‐lasting basal insulin coverage, and insulin aspart, which targets …
[PDF][PDF] Consensus on initiation and intensification of premix insulin in type 2 diabetes management
V Mohan, S Kalra, J Kesavadev, K Singh… - Journal of the …, 2017 - researchgate.net
Introduction: Premix insulin is the most commonly used insulin preparation in India. The first
Indian premix guidelines were developed in 2009 and thereafter were updated in 2013 …
Indian premix guidelines were developed in 2009 and thereafter were updated in 2013 …